Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Blocking Interfering Microbes: Irinotecan is a widely used anticancer pro-drug that is converted in the liver into the active form, but when it gets into the gut, the normally benign microbial flora can convert it into the toxic form, which kills the rapidly multiplying gut epithelium as it would kill rapidly dividing tumor cells, and thus causes diarrhea. Wallace et al. (p. 831 ; see the Perspective by Patel and Kaufmann ) used high-throughput screening to identify inhibitors that target the offending bacterial enzyme, β-glucuronidase, without killing the bacteria or affecting orthologous mammalian enzymes. Crystal structures revealed the molecular basis of selectivity, and in vivo studies showed that an inhibitor protected mice from irinotecan-induced toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“Toxic or adverse consequences can also ensue, as is the case for irinotecan (Wallace et al., 2010)”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
In the citing paper
“Notably, β-glucuronidase inhibitors are capable of rescuing mice from drug toxicity.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“This specificity towards the bacterial enzymes was revealed with the assistance of crystallography and bioinformatics, which demonstrated that these inhibitors interacted with a “bacterial loop” that is highly conserved and well distributed across the gut bacteria enzymes, but is absent from the mammalian enzyme146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“The answer appears to be yes for the bacterial β-glucuronidases, for which multiple inhibitors now exist that have minimal impact on the mammalian homolog143–146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007) · Nature · doi:10.1038/nature06244 · Cited by 6,091
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Gut flora in health and disease
Guarner, F., & Malagelada, J.-R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,365
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
CDD: specific functional annotation with the Conserved Domain Database
Marchler-Bauer, A., Anderson, J. B., Chitsaz, F., Derbyshire, M. K., DeWeese-Scott, C., Fong, J. H., Geer, L. Y., Geer, R. C., Gonzales, N. R., Gwadz, M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn845 · Cited by 1,071
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Three-dimensional structure of β-galactosidase from E. coli.
Jacobson, R. H., Zhang, X.-J., DuBose, R. F., & Matthews, B. W. (1994) · Nature · doi:10.1038/369761a0 · Cited by 600
Research works printed but not linked: 4
- Mathijssen RHJ Clin Cancer Res 7 2182 2001 11489791
- Basińska A Floriańczyk B Ann Univ Mariae Curie Sklodowska Med 58 386 2003 15323223
- Jain S Nat Struct Mol Biol 3 375 1996 · DOI · Paper page
- Brattain MG Fine WD Khaled FM Thompson J Brattain DE Cancer Res 41 1751 1981 7214343
Cited by
Items 301–400 of 1,001
Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
Adiwijaya, B., Kim, J., Láng, I., Csőszi, T., Cubillo, A., Chen, J., Wong, M., Park, J. O., Kim, J., Rau, K.-M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.720 · Cited by 58
Bai, J., Chen, H., & Bai, X. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23810 · Cited by 59
A small molecule inhibitor prevents gut bacterial genotoxin production
Volpe, M. R., Velilla, J. A., Daniel-Ivad, M., Yao, J. J., Stornetta, A., Villalta, P. W., Huang, H., Bachovchin, D. A., Balbo, S., Gaudet, R., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01147-8 · Cited by 61
Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity
Cario, E. (2016) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000202 · Cited by 59
Predicting and Understanding the Human Microbiome’s Impact on Pharmacology
Hitchings, R., & Kelly, L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.04.014 · Cited by 61
Tao, G., Huang, J., Moorthy, B., Wang, C., Hu, M. C., Gao, S., & Ghose, R. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1815705 · Cited by 59
Lin, H., Chen, C.-Y., Lin, T., Yeh, L.-F., Hsieh, W., Gao, S., Burnouf, P., Chen, B., Hsieh, T.-J., Dashnyam, P., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01815-w · Cited by 58
Self-citationA Gut-Restricted Lithocholic Acid Analog as an Inhibitor of Gut Bacterial Bile Salt Hydrolases
Adhikari, A. A., Ramachandran, D., Chaudhari, S. N., Powell, C. E., Li, W., McCurry, M. D., Banks, A. S., & Devlin, A. S. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00192 · Cited by 54
Capula, M., Perán, M., Xu, G., Donati, V. L., Yee, D., Gregori, A., Assaraf, Y. G., Giovannetti, E., & Deng, D. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100864 · Cited by 57
Xiao, J., Chen, H., Kang, D., Shao, Y., Shen, B., Li, X., Yin, X., Zhu, Z., Li, H., Rao, T., et al. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.09.027 · Cited by 56
The human gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs
Guthrie, L., Wolfson, S., & Kelly, L. (2019) · eLife · doi:10.7554/elife.42866 · Cited by 55
Jameson, G., Hamm, J. T., Weiss, G. J., Alemany, C. A., Anthony, S. P., Basche, M., Ramanathan, R. K., Borad, M. J., Tibes, R., Cohn, A. L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1201 · Cited by 55
Wang, J., Feng, W., Zhang, S., Chen, L., Sheng, Y., Tang, F., He, J., Xu, X., Ao, H., & Peng, C. Y. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.111887 · Cited by 56
Komorowski, A. S., & Pezo, R. C. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05472-w · Cited by 57
A data-driven approach for predicting the impact of drugs on the human microbiome
Algavi, Y. M., & Borenstein, E. (2023) · Nature Communications · doi:10.1038/s41467-023-39264-0 · Cited by 54
Michikawa, M., Ichinose, H., Momma, M., Biely, P., Jongkees, S. A. K., Yoshida, M., Kotake, T., Tsumuraya, Y., Withers, S. G., Fujimoto, Z., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.346288 · Cited by 54
Bastos, R. W., Pedroso, S. H. S. P., Vieira, A. T., Moreira, L. M. C., Franca, C. S. L., Cartelle, C. T., Arantes, R. M. E., Generoso, S. V., Cardoso, V. N., Neves, M. J., et al. (2016) · Beneficial Microbes · doi:10.3920/bm2015.0190 · Cited by 56
The Human Microbiota, Infectious Disease, and Global Health: Challenges and Opportunities
Waldman, A. J., & Balskus, E. P. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00232 · Cited by 58
The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental?
Hekmatshoar, Y., Saadat, Y. R., Khatibi, S. M. H., Özkan, T., Vahed, F. Z., Nariman‐Saleh‐Fam, Z., Gargari, B. P., Sunguroğlu, A., & Vahed, S. Z. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116680 · Cited by 56
Arnone, A. A., & Cook, K. L. (2022) · Endocrinology · doi:10.1210/endocr/bqac177 · Cited by 54
Microbiota and kidney disease: the road ahead
Bloom, P. P., Garrett, W. S., Penniston, K. L., Winkler, M. K. H., Hazen, S. L., Agudelo, J., Suryavanshi, M. V., Babiker, A. Y. M., Dodd, D., Fischbach, M. A., et al. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00988-5 · Cited by 55
Self-citationIntracellular Ca2+ Cascade Guided by NIR-II Photothermal Switch for Specific Tumor Therapy
Ma, Z., Zhang, J. C., Zhang, W., Foda, M. F., Zhang, Y., Ge, L., & Han, H. (2020) · iScience · doi:10.1016/j.isci.2020.101049 · Cited by 53
Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives
Degraeve, A. L., Moudio, S., Haufroid, V., Eddour, D. C., Mourad, M., Bindels, L. B., & Elens, L. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1803277 · Cited by 56
Yue, B., Gao, R., Lv, C., Yu, Z., Wang, H., Geng, X., Wang, Z., & Dou, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.774560 · Cited by 55
Self-citationPhenylpropionic acid produced by gut microbiota alleviates acetaminophen-induced hepatotoxicity
Cho, S., Yang, X., Won, K., Leone, V., Hubert, N., Chang, E., Chung, E., Park, J.-S., Guzman, G., Lee, H., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2231590 · Cited by 52
Heterogeneity of colon cancer: from bench to bedside
Merlano, M. C., Granetto, C., Fea, E., Ricci, V., & Garrone, O. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000218 · Cited by 58
Currò, D. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1414598 · Cited by 52
Creekmore, B. C., Gray, J. H., Walton, W. G., Biernat, K. A., Little, M. S., Xu, Y., Liu, J., Gharaibeh, R. Z., & Redinbo, M. R. (2019) · mSystems · doi:10.1128/msystems.00452-19 · Cited by 49
Self-citationHeinken, A., Acharya, G., Ravcheev, D. A., Hertel, J., Nyga, M., Okpala, O. E., Hogan, M., Magnúsdóttir, S., Martinelli, F., Preciat, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.09.375451 · Cited by 57
Changes in Intestinal Flora and Metabolites in Neonates With Breast Milk Jaundice
Li, Y., Shen, N., Li, J., Hu, R., Mo, X., & Xu, L. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.00177 · Cited by 51
Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response
Carr, D. F., Turner, R. M., & Pirmohamed, M. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14407 · Cited by 53
Host-Microbiome Interaction and Cancer: Potential Application in Precision Medicine
Contreras, A. V., Cocom-Chan, B., Hernández‐Montes, G., Portillo-Bobadilla, T., & Reséndis-Antonio, O. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00606 · Cited by 52
How to Determine the Role of the Microbiome in Drug Disposition
Bisanz, J. E., Spanogiannopoulos, P., Pieper, L. M., Bustion, A. E., & Turnbaugh, P. J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083402 · Cited by 55
The Future of Microbiome‐Based Therapeutics in Clinical Applications
Sharma, A., Das, P., Buschmann, M. M., & Gilbert, J. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1677 · Cited by 53
MASS SPECTROMETRY‐BASED PERSONALIZED DRUG THERAPY
Cui, J., Wang, L., Tan, Z., Zhou, H., Zhan, X., & Yin, J. (2020) · Mass Spectrometry Reviews · doi:10.1002/mas.21620 · Cited by 52
Sun, R., Zhu, L., Li, L., Song, W., Gong, X., Qi, X., Wang, Y., Ghose, R., Gao, S., Hu, M., et al. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115032 · Cited by 51
Zidi, O., Souai, N., Raies, H., Ayed, F. B., Mézlini, A., Mezrioui, S., Tranchida, F., Sabatier, J., Mosbah, A., Cherif, A., et al. (2021) · Molecules · doi:10.3390/molecules26082266 · Cited by 52
Taking a metagenomic view of human nutrition
Dutton, R. J., & Turnbaugh, P. J. (2012) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e3283561133 · Cited by 51
Exploring the Potential of Breast Microbiota as Biomarker for Breast Cancer and Therapeutic Response
Dieleman, S., Aarnoutse, R., Ziemons, J., Kooreman, L. F. S., Boleij, A., & Smidt, M. L. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.02.020 · Cited by 50
The Role of Respiratory Microbiota in Lung Cancer
Wang, D., Cheng, J., Zhang, J., Zhou, F., He, X., Shi, Y., & Tao, Y. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.51376 · Cited by 52
Giacomini, K. M., Yee, S. W., Koleske, M. L., Zou, L., Matsson, P., Chen, E. C., Kroetz, D. L., Miller, M. A., Gozalpour, E., & Chu, X. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2627 · Cited by 46
The Colonic Microbiota and Colonic Disease
Shanahan, F. (2012) · Current Gastroenterology Reports · doi:10.1007/s11894-012-0281-5 · Cited by 53
Paulík, A., Nekvindová, J., & Filip, S. (2018) · Tumori Journal · doi:10.1177/0300891618811283 · Cited by 51
Mickoleit, F., Lanzloth, C., & Schüler, D. (2020) · Small · doi:10.1002/smll.201906922 · Cited by 50
Kim, S. H., & Lim, Y. J. (2021) · Intestinal Research · doi:10.5217/ir.2021.00034 · Cited by 49
Understanding and Modulating Mammalian-Microbial Communication for Improved Human Health
Mani, S., Boelsterli, U. A., & Redinbo, M. R. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140007 · Cited by 48
“In contrast, microbial β-glucuronidases appear to be nonessential and are present to scavenge for glucuronide sugar carbon sources (33).”
BackgroundInfluentialSelf-citationExploring the role of gut microbiota in advancing personalized medicine
Huang, G., Khan, R., Zheng, Y., Lee, P.-C., Li, Q., & Khan, I. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1274925 · Cited by 50
Harnessing the Intestinal Microbiome for Optimal Therapeutic Immunomodulation
Viaud, S., Daillère, R., Boneca, I. G., Lepage, P., Pittet, M. J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R., & Zitvogel, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0987 · Cited by 47
Wu, R., Mei, X., Wang, J.-S., Sun, W., Xue, T., Lin, C., & Xu, D. (2019) · Food & Function · doi:10.1039/c9fo01034c · Cited by 48
Urobiome: An outlook on the metagenome of urological diseases
Shoemaker, R., & Kim, J. (2021) · Korean journal of urology · doi:10.4111/icu.20210312 · Cited by 54
Microbiota in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Guan, D., Wang, Z., Li, X., Dong, S., Huang, J., & Zhou, W. (2023) · MedComm · doi:10.1002/mco2.417 · Cited by 50
Gong, T., Liu, X., Wang, X., Lu, Y., & Wang, X. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133623 · Cited by 54
Inoue, A., Deem, A. K., Kopetz, S., Heffernan, T. P., Draetta, G. F., & Carugo, A. (2019) · Cancers · doi:10.3390/cancers11091321 · Cited by 45
Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs
Džidić-Krivić, A., Kusturica, J., Sher, E. K., Selak, N., Osmančević, N., Farhat, E. K., & Sher, F. (2023) · Drug Metabolism Reviews · doi:10.1080/03602532.2023.2186313 · Cited by 49
(2022) · doi:10.1080/19490976.2022.2107289 · Cited by 45
Self-citationSimpson, J. B., Sekela, J. J., Graboski, A. L., Borlandelli, V. B., Barker, N. K., Sorgen, A. A., Bivins, M. M., Mordant, A. L., Johnson, R. L., Bhatt, A. P., et al. (2022) · doi:10.1101/2022.05.19.22274720 · Cited by 45
Self-citationPotential Repurposing of Known Drugs as Potent Bacterial β-Glucuronidase Inhibitors
Ahmad, S., Hughes, M. A., Yeh, L.-A., & Scott, J. E. (2012) · SLAS Discovery · doi:10.1177/1087057112444927 · Cited by 44
Self-citationArtificial intelligence-driven prediction of multiple drug interactions
Chen, S., Li, T., Yang, L., Zhai, F., Jiang, X., Xiang, R., & Ling, G. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac427 · Cited by 45
Progress on the pathological tissue microenvironment barrier-modulated nanomedicine
Han, H., Xing, L., Chen, B., Liu, Y., Zhou, T., Wang, Y., Zhang, L., Li, L., Cho, C., & Jiang, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115051 · Cited by 45
Suvorova, I. A., Tutukina, M. N., Ravcheev, D. A., Rodionov, D. A., Ozoline, O. N., & Gelfand, M. S. (2011) · Journal of Bacteriology · doi:10.1128/jb.00277-11 · Cited by 44
C. elegans: A biosensor for host–microbe interactions
Backes, C., Martínez‐Martínez, D., & Cabreiro, F. (2021) · Lab Animal · doi:10.1038/s41684-021-00724-z · Cited by 45
The past, present, and future of chemotherapy with a focus on individualization of drug dosing
DeRidder, L. B., Rubinson, D. A., Langer, R., & Traverso, G. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.043 · Cited by 46
Cheng, K.-W., Tseng, C.-H., Yang, C., Tzeng, C., Cheng, T.-C., Leu, Y.-L., Chuang, Y.-C., Wang, J., Lu, Y., Chen, Y.-L., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00963 · Cited by 43
Molecular detection of bacterial contamination in gnotobiotic rodent units
Packey, C. D., Shanahan, M. T., Manick, S., Bower, M., Ellermann, M., Tonkonogy, S. L., Carroll, I. M., & Sartor, R. B. (2013) · Gut Microbes · doi:10.4161/gmic.25824 · Cited by 47
Targeting the human gut microbiome with small-molecule inhibitors
Woo, A. Y. M., Aguilar Ramos, M. A., Narayan, R., Richards-Corke, K. C., Wang, M. L., Sandoval-Espinola, W. J., & Balskus, E. P. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00471-4 · Cited by 42
Zhang, L., Dong, C., Wang, J., Liu, M., Wang, J., Hu, J., Liu, L., Liu, X., Xia, C., Zhong, L., et al. (2023) · The ISME Journal · doi:10.1038/s41396-023-01423-y · Cited by 42
Speckmann, B., Ehring, E., Hu, J., & Rodriguez‐Mateos, A. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2305716 · Cited by 43
Microbiome and pancreatic cancer: time to think about chemotherapy
de Castilhos, J., Tillmanns, K., Blessing, J., Larano, A., Borisov, V., & Stein‐Thoeringer, C. K. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2374596 · Cited by 42
The Future of Pharmacogenomics: Integrating Epigenetics, Nutrigenomics, and Beyond
Shaman, J. A. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14121121 · Cited by 45
Wlodarska, M., Johnston, J. C., Gardy, J. L., & Tang, P. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00124-14 · Cited by 43
Basu, S., Zeng, M., Yin, T., Gao, S., & Hu, M. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.02.012 · Cited by 42
Analysis of Domain Architecture and Phylogenetics of Family 2 Glycoside Hydrolases (GH2)
Talens-Perales, D., Górska, A., Huson, D. H., Polaina, J., & Marín‐Navarro, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168035 · Cited by 42
Xu, Y., Feng, X., Jia, J., Chen, X., Jiang, T., Rasool, A., Lv, B., Qu, L., & Li, C. (2018) · Applied and Environmental Microbiology · doi:10.1128/aem.00755-18 · Cited by 42
Consideration of Gut Microbiome in Murine Models of Diseases
Zhang, C., Franklin, C. L., & Ericsson, A. C. (2021) · Microorganisms · doi:10.3390/microorganisms9051062 · Cited by 45
Pharmacomicrobiomics: The Role of the Gut Microbiome in Immunomodulation and Cancer Therapy
Bolte, L. A., Björk, J. R., Gaćeša, R., & Weersma, R. K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.04.025 · Cited by 43
Investigation of Host–Gut Microbiota Modulation of Therapeutic Outcome
Yip, L. Y., & Chan, E. C. Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063750 · Cited by 43
An Ex Vivo Fermentation Screening Platform to Study Drug Metabolism by Human Gut Microbiota
van de Steeg, E., Schuren, F. H. J., Obach, R. S., van Woudenbergh, C., Walker, G. S., Heerikhuisen, M., Nooijen, I., & Vaes, W. H. J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.081026 · Cited by 44
Palko-Łabuz, A., Maksymowicz, J., Sobieszczańska, B., Wikiera, A., Skonieczna, M., Wesołowska, O., & Środa-Pomianek, K. (2021) · Cancers · doi:10.3390/cancers13122952 · Cited by 45
Chen, Y., Chuang, C.-H., Miao, Z., Yip, K., Liu, C., Li, L., Wu, D., Cheng, T., Lin, C., & Wang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.955313 · Cited by 45
Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy
Deng, Y., Hou, X., Wang, H., Du, H., & Liu, Y. (2024) · Pharmaceuticals · doi:10.3390/ph17050604 · Cited by 40
Self-citationGut microbiota interact with breast cancer therapeutics to modulate efficacy
Arnone, A. A., Ansley, K. C., Heeke, A. L., Howard-McNatt, M. M., & Cook, K. L. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00185-0 · Cited by 44
Gut microbiota therapy in gastrointestinal diseases
Ullah, H., Arbab, S., Chang, C., Bibi, S., Muhammad, N., Rehman, S. U., Suleman, S., Ullah, I., Hassan, I. U., Tian, Y., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1514636 · Cited by 42
Chen, M. J., Cheng, K.-W., Chen, Y.-J., Wang, C.-H., Cheng, T.-C., Chang, K.-C., Kao, A., & Chuang, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-03252-4 · Cited by 41
Wei, B., Yang, W., Yan, Z., Zhang, Q., & Yan, R. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.07.013 · Cited by 42
Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability
Flowers, S. A., Bhat, S., & Lee, J. C. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2428 · Cited by 42
Li, Y., He, M., Zhou, T., Wang, Q., He, L., Wang, S., Hu, B., Wei, B., Wang, H., & Cui, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113322 · Cited by 40
Self-citationSchubert, M., Rohrbach, R., Schmitt, M. W., & Stein‐Thoeringer, C. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670286 · Cited by 40
DeClercq, V., Nearing, J. T., & Langille, M. G. I. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261032 · Cited by 40
Briciu-Burghina, C., Heery, B., & Regan, F. B. (2015) · The Analyst · doi:10.1039/c5an01021g · Cited by 40
Elsalem, L., Jum’ah, A. A., Alfaqih, M. A., & Aloudat, O. (2020) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s243337 · Cited by 39
Yin, B., Wang, X., Fang, Y., Li, Y., & Lu, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.899111 · Cited by 40
Kodawara, T., Higashi, T., Negoro, Y., Kamitani, Y., Igarashi, T., Watanabe, K., Tsukamoto, H., Yano, R., Masada, M., Iwasaki, H., et al. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12511 · Cited by 39
Xiong, W., Wang, L., Chen, X., Tang, H., Cao, D., Zhang, G., & Chen, W. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00888e · Cited by 39
Taguer, M., & Maurice, C. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.366 · Cited by 37
Computational methods and challenges in analyzing intratumoral microbiome data
Wang, Q., Liu, Z., Ma, A., Li, Z., Liu, B., & Ma, Q. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.01.011 · Cited by 37
Ghosal, S., Bag, S., Rao, S. R., & Bhowmik, S. (2024) · RSC Advances · doi:10.1039/d4ra04544k · Cited by 42
Mani, S. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.07.004 · Cited by 40
Self-citationSun, Y., Zhang, J., Zhao, A., Li, W., Feng, Q., & Wang, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230197 · Cited by 37
Chaplin, A. M. L., Gao, H., Asase, C., Palanivel, R., Park, B., Skander, D., Bebek, G., Rajagopalan, S., & Maiseyeu, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-69745-x · Cited by 38
Mirror, mirror on the wall: which microbiomes will help heal them all?
Nayak, R. R., & Turnbaugh, P. J. (2016) · BMC Medicine · doi:10.1186/s12916-016-0622-6 · Cited by 36
“This reactivation in the gut also contributes to the dose-limiting diarrheal side effects of irinotecan [27].”
BackgroundInfluential
Metadata
- Authors
- Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., & Redinbo, M. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Albert Einstein College of Medicine (US)
- North Carolina Central University (US)
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 831-835
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3110694
- OpenAlex
- W2140145798
- Cited by
- 1,080
- References
- 39
- Citations by year
- 2026: 97 · 2025: 80 · 2024: 103 · 2023: 101 · 2022: 92 · 2021: 92 · 2020: 100 · 2019: 82 · 2018: 70 · 2017: 67 · 2016: 47 · 2015: 33 · 2014: 34 · 2013: 28 · 2012: 29
- FWCI
- 25.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Damon Runyon Cancer Research Foundation
- Golden LEAF Foundation
- National Institutes of Health
- National Cancer Institute (CA 127231, R01CA161879, R01CA127231, CA98468, R01CA098468)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073338)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, chemotherapy-induced diarrhea, enzyme inhibitors, gut microbiota, commensal bacteria, substrate specificity, crystal structure, high-throughput screening, oral administration, colon cancer, drug toxicity
- MeSH terms
- Irinotecan, Animals, Antineoplastic Agents, Phytogenic, Bacteria, Anaerobic, Camptothecin, Colon, Diarrhea, Drug Evaluation, Preclinical, Enzyme Inhibitors, Escherichia coli, Female, Glucuronidase, Humans, Intestinal Mucosa, Mice, Inbred BALB C, Models, Molecular, Prodrugs, Protein Conformation, Crystallography, X-Ray, Escherichia coli Proteins, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.